Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway
- PMID: 22982254
- DOI: 10.1016/j.neuropharm.2012.08.023
Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway
Abstract
Partial lesion (50%) of the nigro-striatal dopaminergic pathway induces compensatory increase in dopamine release from the remaining neurons and increased extracellular oxidative stress (OS(-ec)) in the striatum. The present study was designed to explore the role of monoamine oxidase types A and B (MAO-A, MAO-B) in producing this increased oxidative stress. Lesion of the dopaminergic pathways in the CNS was produced in rats by intra-cerebroventricular injection of 6-hydroxydopamine (6-OHDA; 250 μg) and striatal microdialysis was carried out 5 weeks later. Striatal OS(ec) was determined by measurement of oxidized derivatives of the marker molecule N-linoleyl-tyrosine. Striatal tissue MAO-A activity was unchanged by 6-OHDA lesion but MAO-B activity was increased by 16%, together with a 45% increase in glial cell content. The selective MAO-B inhibitor rasagiline (0.05 mg/kg s.c. daily for 14 days) did not affect microdialysate dopamine concentration [DA(ec)] in sham-operated rats, but decreased OS(ec) by 30%. In lesioned rats, rasagiline decreased [DA(ec)] by 42% with a 49% reduction in OS(ec). The decrease in [DA(ec)] was reversed by the dopamine D2 receptor antagonist sulpiride (10 mg/kg s.c.). The selective MAO-A inhibitor clorgyline (0.2 mg/kg s.c. daily for 14 days) increased striatal [DA(ec)] by 72% in sham-operated rats with no change in OS(ec). In lesioned rats clorgyline increased [DA(ec)] by 66% and decreased OS(ec) by 44%. Rasagiline and clorgyline were effective to a similar extent in reduction of tissue levels of 7-ketocholesterol and the ratio GSSG/GSH, indicative of reduced intracellular oxidative stress level. This data implies that gliosis in our 6-OHDA animals together with inhibition of glial cell MAO-B by rasagiline causes an increase in local levels of dopamine at the presynaptic receptors, and a reduction in dopamine release (and in [DA(ec)]) by presynaptic inhibition. Moreover, inhibition of MAO-A or MAO-B reduces the enhanced level of oxidative stress in the lesioned striatum, and while both clorgyline and rasagiline reduced DA oxidative metabolism, rasagiline possesses an additional antioxidant property, not only that resulting from MAO inhibition.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
Alterations in striatal oxidative stress level produced by pharmacological manipulation of dopamine as shown by a novel synthetic marker molecule.Neuropharmacology. 2011 Jul-Aug;61(1-2):87-94. doi: 10.1016/j.neuropharm.2011.03.006. Epub 2011 Mar 21. Neuropharmacology. 2011. PMID: 21414328
-
Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea-pig.Br J Pharmacol. 2000 Aug;130(8):1992-8. doi: 10.1038/sj.bjp.0703493. Br J Pharmacol. 2000. PMID: 10952692 Free PMC article.
-
The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons.J Pharmacol Exp Ther. 1980 Nov;215(2):461-8. J Pharmacol Exp Ther. 1980. PMID: 7441510
-
Novel aspects of dopamine oxidative metabolism (confounding outcomes take place of certainties).Pharmacol Toxicol. 2001 Nov;89(5):217-24. doi: 10.1034/j.1600-0773.2001.d01-151.x. Pharmacol Toxicol. 2001. PMID: 11881974 Review.
-
Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.Mech Ageing Dev. 2005 Feb;126(2):317-26. doi: 10.1016/j.mad.2004.08.023. Mech Ageing Dev. 2005. PMID: 15621213 Review.
Cited by
-
Selectivity of Dietary Phenolics for Inhibition of Human Monoamine Oxidases A and B.Biomed Res Int. 2019 Jan 23;2019:8361858. doi: 10.1155/2019/8361858. eCollection 2019. Biomed Res Int. 2019. PMID: 30809547 Free PMC article.
-
N-(furan-2-ylmethyl)-N-methylprop-2-yn-1-amine (F2MPA): A potential cognitive enhancer with MAO inhibitor properties.CNS Neurosci Ther. 2014 Jul;20(7):633-40. doi: 10.1111/cns.12284. Epub 2014 May 21. CNS Neurosci Ther. 2014. PMID: 24848125 Free PMC article.
-
Kinetics of Inhibition of Monoamine Oxidase Using Curcumin and Ellagic Acid.Pharmacogn Mag. 2016 May;12(Suppl 2):S116-20. doi: 10.4103/0973-1296.182168. Epub 2016 May 11. Pharmacogn Mag. 2016. PMID: 27279695 Free PMC article.
-
Dereplication of Components Coupled with HPLC-qTOF-MS in the Active Fraction of Humulus japonicus and It's Protective Effects against Parkinson's Disease Mouse Model.Molecules. 2019 Apr 11;24(7):1435. doi: 10.3390/molecules24071435. Molecules. 2019. PMID: 30979037 Free PMC article.
-
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology.Front Pharmacol. 2016 Oct 18;7:340. doi: 10.3389/fphar.2016.00340. eCollection 2016. Front Pharmacol. 2016. PMID: 27803666 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources